🔗 Permalink

Inventor profile of:

Daniel B. DIX

City:

LaGrangeville, New York

Country:

United States

Published Applications:

Last publication date:

2026-01-22

Top Assignees for applications by Daniel B. DIX

The entities that hold a legal rights for patent applications filed by inventor DIX Daniel B.:

Regeneron Pharmaceuticals, Inc. 29 Tarrytown, NY United States

Recent patent applications by DIX Daniel B.

Daniel B. DIX from LaGrangeville, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-01-22

US20260022183A1

Chemistry; metallurgy

Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies

#2 | 2026-01-22

US20260022182A1

Chemistry; metallurgy

Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies

#3 | 2025-09-11

US20250281618A1

Human necessities

PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION

#4 | 2025-06-19

US20250197515A1

Chemistry; metallurgy

STABILIZED FORMULATIONS CONTAINING ANTI-INTERLEUKIN-6 RECEPTOR (IL-6R) ANTIBODIES

#5 | 2025-05-22

US20250161457A1

Human necessities

PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION

#6 | 2024-12-19

US20240415969A1

Human necessities

PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION

#7 | 2024-10-31

US20240360230A1

Chemistry; metallurgy

Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies

#8 | 2023-12-21

US20230406959A1

Chemistry; metallurgy

STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES

#9 | 2021-12-30

US20210403581A1

Chemistry; metallurgy

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

#10 | 2021-12-23

US20210393778A1

Human necessities

VEGF Antagonist Formulations

#11 | 2021-12-23

US20210393530A1

Human necessities

VEGF Antagonist Formulations

#12 | 2021-08-19

US20210252147A1

Human necessities

VEGF Antagonist Formulations

#13 | 2021-08-19

US20210252105A1

Human necessities

VEGF Antagonist Formulations

#14 | 2021-07-29

US20210230283A1

Chemistry; metallurgy

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

#15 | 2021-03-18

US20210077624A1

Human necessities

Citrate buffered VEGF antagonist formulations

#16 | 2021-02-25

US20210054100A1

Chemistry; metallurgy

Stabilized formulations containing anti-PCSK9 antibodies

#17 | 2019-12-26

US20190388539A1

Human necessities

Formulations of VEG antagonist fusion proteins and method of manufacturing them

#18 | 2019-12-05

US20190367624A1

Chemistry; metallurgy

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

#19 | 2019-09-19

US20190284301A1

Chemistry; metallurgy

Stabilized formulations containing anti-PCSK9 antibodies

#20 | 2019-08-01

US20190231877A1

Human necessities

Process for reducing subvisible particles in a pharmaceutical formulation

#21 | 2019-01-03

US20190002574A1

Chemistry; metallurgy

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

#22 | 2018-02-15

US20180044436A1

Chemistry; metallurgy

Stabilized formulations containing anti-PCSK9 antibodies

#23 | 2018-01-04

US20180002426A1

Chemistry; metallurgy

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

#24 | 2017-12-21

US20170360930A1

Human necessities

Method of manufacturing VEGF antagonist fusion proteins

#25 | 2017-03-16

US20170073407A1

Chemistry; metallurgy

VEGF ANTAGONIST FORMULATIONS

#26 | 2016-08-25

US20160244505A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#27 | 2016-08-25

US20160244504A1

Chemistry; metallurgy

VEGF specific fusion protein antagonist formulations

#28 | 2016-04-14

US20160102147A1

Chemistry; metallurgy

Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies

#29 | 2016-02-04

US20160032015A1

Chemistry; metallurgy

Stabilized Formulations Containing Anti-PCSK9 Antibodies

#30 | 2016-01-07

US20160002341A1

Chemistry; metallurgy

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

#31 | 2015-04-09

US20150100030A1

Chemistry; metallurgy

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

#32 | 2014-11-20

US20140341928A1

Chemistry; metallurgy

Stabilized formulations containing anti-PCSK9 antibodies

#33 | 2013-07-25

US20130186797A1

Human necessities

Stabilized formulations containing anti-Ang2 antibodies

#34 | 2012-04-26

US20120097565A1

Chemistry; metallurgy

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

#35 | 2011-07-14

US20110171241A1

Chemistry; metallurgy

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

InventorID:

350108 ⎘